|
 "We are surprised and very disappointed that Mydicar failed to meet
the endpoints in the CUPID2 trial, and we are rigorously analyzing
the data in an attempt to better understand the observed outcome,"
Celladon's chief executive, Krisztina Zsebo, said in a statement on
Sunday.
According to the company, the gene therapy failed to show a
significant treatment effect when compared to placebo.
The company said it plans to hold an investor conference call to
discuss the trial on Monday.
Investors have been waiting for the test data, with the options
market expecting an explosive move from the shares when it is
released.
Gene therapies aim to insert corrective genes into malfunctioning
cells. Celladon's Mydicar is a virus designed to deliver a gene that
reconstitutes an enzyme responsible for heart muscle contraction.
The treatment was granted both "breakthrough" and "fast-track"
status by the U.S. Food and Drug Administration.
[to top of second column] |
Shares of Celladon closed at $13.68 on the Nasdaq on Friday.
(Reporting by Michael Erman; Editing by Leslie Adler)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
